- Home
- ESLA vs MNDO Comparison
ESLA vs MNDO Comparison
Compare ESLA & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- MNDO
- Stock Information
- Founded
- ESLA 2021
- MNDO 1995
- Country
- ESLA United States
- MNDO Israel
- Employees
- ESLA N/A
- MNDO N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- MNDO EDP Services
- Sector
- ESLA Health Care
- MNDO Technology
- Exchange
- ESLA Nasdaq
- MNDO Nasdaq
- Market Cap
- ESLA 35.5M
- MNDO 29.3M
- IPO Year
- ESLA N/A
- MNDO 2000
- Fundamental
- Price
- ESLA $0.88
- MNDO $1.40
- Analyst Decision
- ESLA Strong Buy
- MNDO
- Analyst Count
- ESLA 1
- MNDO 0
- Target Price
- ESLA $16.00
- MNDO N/A
- AVG Volume (30 Days)
- ESLA 18.4K
- MNDO 27.8K
- Earning Date
- ESLA 08-20-2025
- MNDO 08-12-2025
- Dividend Yield
- ESLA N/A
- MNDO 15.60%
- EPS Growth
- ESLA N/A
- MNDO N/A
- EPS
- ESLA N/A
- MNDO 0.17
- Revenue
- ESLA N/A
- MNDO $20,677,000.00
- Revenue This Year
- ESLA N/A
- MNDO N/A
- Revenue Next Year
- ESLA N/A
- MNDO N/A
- P/E Ratio
- ESLA N/A
- MNDO $8.29
- Revenue Growth
- ESLA N/A
- MNDO N/A
- 52 Week Low
- ESLA $0.63
- MNDO $1.31
- 52 Week High
- ESLA $1.97
- MNDO $2.13
- Technical
- Relative Strength Index (RSI)
- ESLA 46.61
- MNDO 44.51
- Support Level
- ESLA $0.83
- MNDO $1.40
- Resistance Level
- ESLA $0.95
- MNDO $1.50
- Average True Range (ATR)
- ESLA 0.07
- MNDO 0.05
- MACD
- ESLA 0.01
- MNDO -0.00
- Stochastic Oscillator
- ESLA 55.88
- MNDO 1.92
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.